Islam Badawy, DO
Interventional Cardiology · Crown Point, INNPI 1922425453
Payments from drug & device makers
Across 285 payments — averaging $38.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Philips North America LLC$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$949
- Boston Scientific$838
- Boehringer Ingelheim$597
- Abiomed$592
- plus $4K from 33 others
What the payments were for
- Travel & lodging$2,07619%
- Food & beverage$8,59178%
- Education$3263%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 36 | $2,188 |
| Philips North America LLC | 10 | $1,649 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 32 | $949 |
| Boston Scientific | 7 | $838 |
| Boehringer Ingelheim | 20 | $597 |
| Abiomed | 14 | $592 |
| Johnson & Johnson | 27 | $420 |
| Abbott | 7 | $365 |
| Novartis | 22 | $362 |
| AstraZeneca | 10 | $321 |
| Merck | 14 | $310 |
| Cardiovascular Systems Inc. | 4 | $291 |
| Esperion Therapeutics, Inc. | 7 | $207 |
| Penumbra, Inc. | 2 | $200 |
| Chiesi USA, Inc. | 13 | $197 |
| Alnylam Pharmaceuticals Inc. | 7 | $174 |
| Pfizer | 10 | $164 |
| Kestra Medical Technology Services, Inc. | 7 | $140 |
| Shockwave Medical, Inc | 2 | $138 |
| Amgen | 7 | $118 |
| Stryker | 1 | $102 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
| Inari Medical, Inc. | 4 | $96 |
| W. L. Gore & Associates, Inc. | 2 | $95 |
| Edwards Lifesciences | 3 | $66 |
| Itamar Medical Inc | 1 | $45 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $30 |
| Avinger Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Bayer | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $17 |
| EKOS Corporation | 1 | $16 |
| Terumo Medical Corporation | 1 | $14 |
| Cordis US CORP. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (BQ9) Coronary IVUS$1,247
- Abre$968
- WATCHMAN FLX$407
- VASCULAR$263
- VERQUVO$227
- SYMPLICITY G3$185
- Ensite Cardiac Mapping System$151
- IN.PACT Admiral$148
- (6574) Coronary Other$143
- Diamondback Peripheral$138
- JARDIANCE$125
- Impella$125
- Indigo System$122
- (6346) Intrasight Mobile$121
- HawkOne$114
- MAMBA$114
- NEXLIZET$112
- NEXLETOL$112
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$111
- FARXIGA$105
How this compares
$11,007 in reported general payments places this provider in the 55th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $97,045 |
| EntrestoSacubitril/Valsartan | 19 | $31,028 |
| XareltoRivaroxaban | 28 | $26,244 |
| Repatha SureclickEvolocumab | 20 | $21,827 |
| BrilintaTicagrelor | 24 | $17,625 |
| JardianceEmpagliflozin | 13 | $10,977 |
| ClopidogrelClopidogrel Bisulfate | 161 | $1,690 |
| Rosuvastatin Calcium | 87 | $1,411 |
| Atorvastatin Calcium | 156 | $1,079 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 51 | $855 |
| Metoprolol Succinate | 95 | $758 |
| Labetalol Hcl | 12 | $672 |
| Potassium Chloride | 30 | $616 |
| Ezetimibe | 15 | $546 |
| Carvedilol | 71 | $500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $97,04595 claims |
| NovartisEntresto | $362 | $31,02819 claims |
| Johnson & JohnsonXarelto | $420 | $26,24428 claims |
| AstraZenecaBrilinta | $321 | $17,62524 claims |
| Boehringer IngelheimJardiance | $597 | $10,97713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Crown Point
- James HermillerIndianapolis$2.8M
- Jithendra ChoudaryRichmond$1.6M
- Jeffrey BreallIndianapolis$955K
- Samer AbbasEast Chicago$625K
- Jarrod FrizzellEvansville$559K
- Brian BigelowIndianapolis$444K
- Saeed ShaikhIndianapolis$366K
- Dean FerreraEast Chicago$298K
- Woodrow CoreyIndianapolis$262K
- Navneet LatherNoblesville$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.